Gordon Gary B. 4

What Happened
Gary B. Gordon, a director of TriSalus Life Sciences, purchased 10,000 shares of TLSI on 2026-05-15 at $2.46 per share, a total cash outlay of $24,600. This was reported on a Form 4 filed with the SEC on 2026-05-18. The transaction is a straightforward purchase (Form 4 code "P"), which retail investors often view as a more informative signal than routine insider sales.

Key Details

• Transaction date and price: 2026-05-15; 10,000 shares @ $2.46 each.
• Total value: $24,600.
• Transaction type: Purchase (open-market or private purchase; Form 4 code P).
• Shares owned after transaction: Not specified in the information provided—check the official Form 4 for post-transaction holdings.
• Footnotes/plan info: None indicated in the supplied summary (no 10b5-1, tax withholding, or grant noted).
• Filing timeliness: Form 4 was filed on 2026-05-18 for the May 15 trade (three calendar days later). If May 15 was a business day, this could fall outside the SEC’s standard two-business-day Form 4 filing window—confirm timeliness on the official filing.

Context
This was a cash purchase, not an option exercise, gift, or award. The size ($24.6k) is modest relative to institutional trades or large insider buys, but a director purchase still may be of interest to investors tracking insider activity. For full context, review the official Form 4 for Gordon’s total holdings and any related disclosures.